Correspondence
Survival benefit of neoadjuvant chemoradiation or apples and oranges revisited
P. Mroczkowski,
P. Mroczkowski
Department for General and Visceral Surgery, Elisabeth-Hospital-Kassel, Weinbergstr. 7, 34117 Kassel, Germany
An Institute for Quality Assurance in Operative Medicine Ltd., Otto-von-Guericke-University of Magdeburg, Leipziger Str.44, 39120 Magdeburg, Germany
Search for more papers by this author
P. Mroczkowski,
P. Mroczkowski
Department for General and Visceral Surgery, Elisabeth-Hospital-Kassel, Weinbergstr. 7, 34117 Kassel, Germany
An Institute for Quality Assurance in Operative Medicine Ltd., Otto-von-Guericke-University of Magdeburg, Leipziger Str.44, 39120 Magdeburg, Germany
Search for more papers by this author
First published: 15 March 2018
No abstract is available for this article.
References
- 1Sun Z, Adam MA, Kim J et al. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Dis 2017; 19: 1058–66.
- 2Wibe A, Law WL, Fazio V, Delaney CP. Tailored rectal cancer treatment–a time for implementing contemporary prognostic factors? Colorectal Dis 2013; 15: 1333–42.
- 3Glimelius B, Myklebust TA, Lundqvist K, Wibe A, Guren MG. Two countries–two treatment strategies for rectal cancer. Radiother Oncol 2016; 121: 357–63.
- 4Battersby NJ, Juul T, Christensen P et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study. Dis Colon Rectum 2016; 59: 270–80.
- 5Battersby NJ, How P, Moran B et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016; 263: 751–60.
